好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Damage of Different CNS Compartments Contributes to Explain Multiple Sclerosis Disability Milestones: A Multicenter Study
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
154

To perform a multiparametric assessment of cortical, deep (D) grey matter (GM), cerebellar and cervical cord damage and determine their relative contributions to the main clinical disability milestones of multiple sclerosis (MS).

In MS, inflammation and neurodegeneration involve several cortical and subcortical central nervous system structures.

3T brain and cervical cord T2- and 3D T1-weigthed images were acquired from 198 MS patients (139 relapsing-remitting [RR] MS, 59 progressive [P] MS) and 67 healthy controls (HC) at three European sites. Brain and cervical cord lesion burden, cortical thickness (CTh), whole-GM, DGM and cerebellar volumetry, as well as cord cross-sectional area (CSA) were quantified. Random forest analyses identified predictors of the expanded disability status scale (EDSS) score and determined the main contributors to different disability milestones (EDSS=3.0, 4.0 and 6.0).

 

Compared to HC, MS patients had widespread atrophy in all investigated compartments (p=range <0.001-0.05). In MS patients, lower cord CSA, higher number of cord lesions and reduced whole-GM volume predicted the EDSS score (out-of-bag R2=0.59, p range=<0.001-0.003). The main determinants of an EDSS score=3.0 were reduced cord CSA, higher brain lesion volume and thalamic atrophy, together with smaller whole-GM and cerebellar volumes (out-of-bag accuracy=0.81, p range=<0.001-0.04). Conversely, reaching an EDSS score=4.0 was mainly predicted by reduced whole-GM volume and cord area, reduced CTh of the frontal and sensorimotor cortices, a higher number of cord lesions and higher cerebellar and DGM atrophy (out-of-bag accuracy=0.84, p range=<0.001-0.04). Finally, a lower cord CSA (p=0.001) and higher number of cord lesions (p=0.003) were the only predictors of EDSS=6.0 (out-of-bag accuracy=0.83).

Random forest analyses identified the peculiar contribution of each CNS compartment to different EDSS milestones. While lesion burden, brain GM and thalamic atrophy were the main determinants of EDSS=3.0 and 4.0, cervical cord damage was predominant to explain an EDSS=6.0.

Authors/Disclosures
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit)
PRESENTER
Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Paola Valsasina Paola Valsasina has nothing to disclose.
Milagros Hidalgo de la Cruz Milagros Hidalgo de la Cruz has nothing to disclose.
Alessandro Meani Alessandro Meani has nothing to disclose.
Claudio Gobbi, MD (Ospedale Regionale Lugano) Dr. Gobbi has nothing to disclose.
Antonio Gallo Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Antonio Gallo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis.
Chiara Zecca, MD (Ente ospedaliero cantonale) Prof. Zecca has nothing to disclose.
Alvino Bisecco Alvino Bisecco has nothing to disclose.
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.